34-1600

antibody from Invitrogen Antibodies

Targeting: CLDN5 AWAL, BEC1, CPETRL1, TMVCF

Provider product page for 34-1600

Western blot

ELISA

Other assay

Antibody data

Antibody Data
Antigen structure
References [160]
Comments [0]
Validations
Other assay [18]

Submit

Product number: 34-1600 - Provider product page
Provider: Invitrogen Antibodies
Product name: Claudin 5 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Reactivity: Human, Mouse
Host: Rabbit
Isotype: IgG
Vial size: 100 µg
Concentration: 0.25 mg/mL
Storage: -20°C

CLDN5 protein structure - 34-1600 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 10. Impact of silencing claudin-3 on Can 10 polarity. Cells transfected either by Lipofectamine with no siRNA, scrambled siRNA or three different claudin-3 siRNA were examined 48 h after tranfection. ( A ) RT-qPCR of one representative experiment. Claudin-3 mRNA level is expressed as the percentage of the level of cells treated with no siRNA. ( B ) western blot. An immunoblot corresponding to the experiment shown in A is presented on the left. Densitometric analysis of immunoblots obtained from three independent experiments is on the right. Claudin-3 level, normalized with alpha-tubulin as internal control, was expressed as the percentage of claudin-3 level of cells treated with no siRNA. ( C ) Analysis of cells forming bile canaliculi. Values are means of three independent experiments. ( D ) Co-localization of claudin-3 with ZO-1, and claudin-5 with occludin, studied by confocal microscopy. In each case, the localization of each tight junction protein (compilation of 20-27 xy sections) is shown, followed by a composite image (interferentiel contrast image with the merge image) (right). For cells treated with claudin-3 siRNA2, xz sections taken as indicated (thin white lines) on the corresponding xy compilations are also presented. Bar, 10 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 1 Expression of TJPs in different leukocyte subsets. Immunofluorescence staining of PBLs from healthy controls with antibodies against claudin 1 or claudin 5 (green) and CD20 (A,B), CD14 (C,D), CD3 (E,F), CD4 (G,H), CD8 (I,J), ZO-1 (K,L) and ZO-2 (M,N) (all red) and a nuclear dye (TO-PRO 3-blue). Scale bar: 5 mum. Representative results from three independent experiments are shown.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Claudin-5 and claudin-4 are expressed in endothelial cells in the developing brain a - d . Cld-5 immunoreactivity in the developing and adult brain. Parenchymal vessels are labeled ( green ) in E19 ( arrows a ) or adult ( arrows b , d ) animals. In c , the anti-Cld-5 polyclonal antibody was used to show the colocalization of the TJ protein ( red ) with the endothelial marker RECA-1 ( green ) in a P2 animal. In all CPs immunodetection revealed a signal associated with the largest vessels penetrating the choroidal stroma ( arrowheads b , d ), but not with the choroidal epithelium, labeled in red by anti-Cld-1 Ab ( d ). Note that all cisternal vessels such as the vein of Galen are also labeled by anti-Cld-5 Ab. DAPI was used for nuclei staining. e Representative Western blot of Cld-4. Brain cortex ( lane 1 20 mug) and MV ( lanes 2 and 3 40 mug) were isolated from adult animals. Lane 4 was loaded with MDCK (10 mug) as positive control. A low, but specific Cld-4 signal was detected in MV ( upper panel lane 3 band at 22 kDa), but not in cortex or in MV when the primary antibody was omitted ( lane 2 ). Actin used as a loading indicator is shown in the lower panel (42 kDa band). Due to the high expression of Cld-4 in MDCK cells, lane 4 was treated separately from the other lanes for HRP detection. f - h Cld-4 immunoreactivity ( red ) in the developing and adult brain. Double immunolabeling with anti-RECA-1Ab ( green ) allowed visualizing the parenchymal vessels that were posit

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Nf1 Loss or HRas Activation in the Optic Nerve Causes Changes in Claudins and BBB Permeability (A) Electron micrographs of optic-nerve cross-sections of capillaries 1 mm from the chiasm (50,000x; scale bar, 200nm) show electron-dense TJs between endothelial cells. Blue arrowheads: areas of TJ disruption. (B) Quantification of the total TJs with gaps, with 200-300 TJs counted per genotype. (C) Evans blue stain of longitudinal sections of PLPCre; Nf1fl / fl and CNP-HRas optic nerve. Insets: cross-sections; arrows: blood vessel. (D) Western blots from total optic-nerve lysates showing claudin-1 and claudin-5. All experiments included three to five animals per genotype. *p < 0.001. See also Figure S5 .

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Individual BBB components are affected in the Ngamma1-KO brains. ( a ) Immunohistochemistry shows that astrocytic endfeet marker AQP4 is expressed at high level in Ctr mice, but dramatically reduced in Ngamma1-KO mice. High power confocal Z-projection images show that AQP4 co-localizes with endothelial cell marker CD31 in Ctr but not Ngamma1-KO brains. ( b ) Occludin and claudin-5, but not PDGFRbeta, are significantly decreased in Ngamma1-KO brains. ( c ) Representative Western blot of AQP4, occludin, claudin-5, PDGFRbeta, and actin using striatum lysates from Ctr and Ngamma1-KO mice. Full blots of these proteins are shown in Supplementary Figure 14 a . Western blot was quantified by densitometry. All bands were normalized to actin (n=6). Scale bars represent 100 mum (low magnification images in a and b ) and 20 mum (high magnification images in a). Data are shown as mean +- sd. *p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Protein levels of claudin-1, -2, -4 and -5 in equine tissues. Levels were measured by western blot (A) and were normalized against GAPDH protein (B-E; claudin-1, -2, -4 and -5, respectively). The signal intensity of each band was measured using the NIH Image J software (USA). Data are presented as the means +- standard error of the mean of four equine samples. Liv, Liver; Kid, Kidney; Lu, Lung; Duo, Duodenum; Hrt, Heart; Tes, Testis; Ov, Ovary; Ut, Uterus. * p < 0.01 vs . liver; + p < 0.01 vs . kidney; ++ p < 0.01 vs . lung; SS p < 0.01 vs . duodenum; p < 0.01 vs . heart; P p < 0.01 vs . ovary; ** p < 0.05 vs . uterus.